This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
I agree with Shavin et al (Arch Dermatol 114: 1679-1680, 1978) that "safe therapeutic measures for Mucha-Habermann's disease in children are lacking." They describe one child and two adolescents whose Mucha-Habermann's disease resolved while they were being treated with erythromycin. As Shavin et al stated, the disease is not uncommon in children and I have seen four to eight patients per year at The Children's Hospital of Buffalo. For those patients with significant scarring disease, we have tried multiple therapeutic modalities, including erythromycin, tetracycline, and prednisone. These studies have not been double blind or randomized; erythromycin was given as a first choice to all patients under 12 years of age, while tetracycline was used in our older patients. Prednisone was the second choice to either antibiotic in the nonresponders.No consistently beneficial response was noted in eight patients treated with erythromycin for a minimum of six weeks
Rasmussen JE. Mucha-Habermann's Disease. Arch Dermatol. 1979;115(6):676–677. doi:10.1001/archderm.1979.04010060002009
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: